EWP
RPRX icon

Elevation Wealth Partners’s Royalty Pharma RPRX Stock Holding History

Elevation Wealth Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Hold
486
– – 0.01% 487
2026
Q1 		$23.3K Hold
486
– – 0.01% 350
2025
Q4 		$18.8K Buy
486
+422
+659% +$16.1K 0.01% 386
2025
Q3 		$2.26K Buy
+64
New +$2.32K ﹤0.01% 621

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elevation Wealth Partners's RPRX Position: Q2 2026 in Review

Elevation Wealth Partners held its Royalty Pharma (RPRX) position steady in Q2 2026 at 486 shares worth $27.3K. The position accounts for 0.01% of the portfolio, ranked #487.

Elevation Wealth Partners first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Elevation Wealth Partners held 486 shares of Royalty Pharma worth $27.3K as of Q2 2026.
  • Elevation Wealth Partners left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #487 holding.
  • Elevation Wealth Partners first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.